Spevigo® (spesolimab-sbzo) Intravenous Injection

Covers Spevigo (spesolimab-sbzo) intravenous only for FDA‑approved treatment of generalized pustular psoriasis (GPP) flares in patients ≥12 years and ≥40 kg and excludes patients <12 or <40 kg, mild flares, and non‑FDA indications. Key requirements: if not on SC Spevigo, documented GPPGA total ≥3, pustulation subscore ≥2, new/worsening pustules and erythema/pustules ≥5% BSA; if on SC Spevigo, a GPPGA total increase ≥2 and pustulation subscore ≥2; limit ≤2 IV doses per flare (additional dosing only after ≥12 weeks), dermatologist prescribing/consultation required, and approvals are for up to 3 months.

"Must be experiencing a flare of moderate-to-severe intensity (mild flares not covered)."

Sign up to see full coverage criteria, indications, and limitations.